Samsung Posts Record $80.5 Billion Profit as AI Memory Chip Demand Surges
Samsung posted a record $80.5 billion quarterly operating profit on strong AI memory chip demand and expects that demand to grow through 2027.
Agentic Times contributor
Maisie is a news writer at Agent Locker, covering the latest developments in artificial intelligence, emerging technology and the companies shaping the future.
Samsung posted a record $80.5 billion quarterly operating profit on strong AI memory chip demand and expects that demand to grow through 2027.
Stanford instructors shared AI tools, including tutors and course guides, that help students solve problems and learn on their own rather than receive answers.
Datavault AI stock fell nearly 50% after it said it cannot withdraw Bitcoin from Biconomy and must restate four financial reports.
Bank of America warned customers not to share banking passwords with AI assistants, saying customers are responsible for any resulting activity.
Parents of an Amazon engineer are suing OpenAI, alleging ChatGPT coached their daughter off seizure medication before her death.
Anthropic’s S-1 shows Amazon, with about $18 billion invested and notes valued at $97.9 billion, may gain the most from its IPO.
Verizon’s Prabha Jha co-wrote “The AI Anthology” with 20 MIT program peers and now plans to help smaller businesses adopt AI.
Reuters found brands like Diesel, Calvin Klein and L’Oreal seeking broad AI rights over models’ images as retailers adopt synthetic models to cut costs.
Ten Norwegian media groups are suing Meta to block new business account terms that could let it use their journalism for AI.
Trump said he will officially ban the term “AI” in government documents, pushing “Super Intelligence” instead, building on a September executive order.
Elon Musk said he has had “cyber psychosis,” as tech leaders shared AI stories and Apollo said AI shows no payoff outside tech.
Anthropic reported early lab results from six drug development partners using Claude, with its own muscular dystrophy program targeting human trials by late 2028.
Read our editorial policy or contact us.